SYMBIOTEC · NSE
Symbiotec Pharmalab Limited
₹1,598.6
-0.39% (-₹6.2)
Prev. close
₹1,604.8
Volume
2,94,589
Delivery %
37.8%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
none in range
Long-Horizon
1 · 1 bull / 0 neutral / 0 bear
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
Long-Horizon calls · 1yr+ horizon · verdict pending
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Motilal Oswal is bullish on Symbiotec Pharmalab, with a target price of ₹1,430 against its current market price of ₹1,16…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Symbiotec Pharmalab | HIT |
Fundamentals
About Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited develops, manufactures, and markets active pharmaceutical ingredients (APIs) in India. The company provides cortico-steroid and hormone (Steroid) APIs; nutraceuticals; and other services. The company was founded in 1995 and is based in Indore, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Anil Satwani
Headquarters
Indore
Employees
1,915
Website
symbiotec.comExchange
View on NSE ↗Key stats
Market cap
₹6,718.62 Cr
P/E ratio (TTM)
84.3
Dividend yield
0.00%
EPS (TTM)
₹14.63
Shares float
2.54 Cr
EPS · quarter ended Jun 2026
₹2.19
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹545.78 Cr | ₹716.25 Cr | ₹751.55 Cr | ₹869.15 Cr | |
EBITDA | ₹72.17 Cr | ₹177.04 Cr | ₹206.11 Cr | ₹231.97 Cr |
| ₹23.47 Cr | ₹100.18 Cr | ₹96.78 Cr | ₹109.88 Cr | |
Diluted EPS | ₹3.65 | ₹15.59 | ₹15.06 | ₹17.1 |
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹989.99 Cr | ₹1,294.79 Cr | ₹1,579.65 Cr | ₹1,780.79 Cr | |
| ₹219.96 Cr | ₹250.60 Cr | ₹544.44 Cr | ₹390.99 Cr | |
Stockholders' equity | ₹621.53 Cr | ₹715.05 Cr | ₹814.89 Cr | ₹1,149.73 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹69.24 Cr | ₹187.50 Cr | ₹47.26 Cr | ₹174.59 Cr | |
Investing cash flow | ₹-219.99 Cr | ₹-206.41 Cr | ₹-306.52 Cr | ₹-226.93 Cr |
| ₹146.14 Cr | ₹21.85 Cr | ₹278.16 Cr | ₹35.99 Cr | |
Capital expenditure | ₹-224.39 Cr | ₹-209.77 Cr | ₹-308.12 Cr | ₹-225.72 Cr |
End cash position | ₹4.55 Cr | ₹7.50 Cr | ₹26.39 Cr | ₹10.04 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 26 |
|---|---|
| Promoter | 33.28% |
| Public | 66.72% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Symbiotec Pharmalab Limited | ₹6,718.62 Cr | ₹1,233.2 | 86.3 | 5.84 | 9.6% | 0.34 | +15.6% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.